Clot-busters safe for treating moderate pulmonary embolism
Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
Researchers found that using half the usual dose of the thrombolytic drug tissue plasminogen activator (t-PA) not only effectively dissolved clots in patients with moderate pulmonary embolism, but also led to earlier hospital discharge and reduced the rate of pulmonary hypertension and recurrent pulmonary embolism without causing bleeding or other major side effects.
Currently, only about 5 percent of pulmonary embolism cases are considered severe enough to be given thrombolytic agents at full dose. While these drugs are effective in dissolving blood clots, they carry a 2 percent to 6 percent risk of causing dangerous bleeding inside the brain. The vast majority of pulmonary embolism cases are considered moderate, and thus are typically treated with anticoagulants (anti-clotting agents). However, even moderate cases can lead to recurring pulmonary embolism, pulmonary hypertension and other dangerous complications.
"Pulmonary embolism can be more aggressively and above all, safely managed with what we call 'safe-dose thrombolysis,'" said Mohsen Sharifi, MD, director of Arizona Cardiovascular Consultants and the study's lead investigator. "Eighty percent, or more, of pulmonary embolism patients would benefit from this treatment."
Other research has investigated the use of thrombolytics for moderate pulmonary embolism, but this is the first study to show that using a lower dose of t-PA and anticoagulants can be safe and effective for such patients. These findings could ultimately change the way doctors handle hundreds of thousands of cases each year.
Pulmonary embolism, a complication of deep vein thrombosis, occurs when a blood clot becomes lodged in a lung artery after traveling there from elsewhere in the body, typically the legs. It can lead to death if left untreated.
Dr. Sharifi said expanding the use of "safe-dose thrombolysis" to more aggressively treat moderate pulmonary embolism could help prevent patients from developing more serious complications later on. He further emphasized the need to lower the dose of anticoagulants given along with t-PA.
"Moderate pulmonary embolism may be the tip of the iceberg," said Dr. Sharifi. "These patients might be doing okay initially, but ultimately, in the subsequent few years, they may develop complications."
The study enrolled 121 patients with moderate pulmonary embolism and gave 61 of them a half-dose of thrombolytic drugs with a modified regimen of anticoagulants. Sixty were given anticoagulants alone. Patients were tracked for 28 months.
In addition to treating severe pulmonary embolism, thrombolysis is commonly used to dissolve the blood clots that cause heart attacks and strokes.
More information: Dr. Sharifi will present the study "Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT Study)" on Tuesday, March 27 at 8 a.m. during the Joint ACC/JAMA Late-Breaking Clinical Trials in McCormick Place North: Main Tent.
Provided by
American College of Cardiology
-
'Clot-busters' no more effective than traditional therapy in treating lung blood clots
May 16, 2011 |
not rated yet |
0
-
Risk of pulmonary embolism greatest during first week following total joint replacement
Feb 07, 2012 |
not rated yet |
0
-
Are blood thinners post-op killers?
Mar 31, 2008 |
not rated yet |
0
-
Clearing the way for detecting pulmonary embolism
Dec 01, 2009 |
not rated yet |
0
-
Consider the breast and lungs when determining thoracic imaging protocols
Oct 01, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Calculating on-axis elements of a solenoid
4 hours ago
-
latitude & longitude & air pressure
5 hours ago
-
Differences of Classical Mechanics when learned with Calc vs algebra?
8 hours ago
-
what is the distance traveled
12 hours ago
-
Image of a Convex Lens Cut in Half Horizontally
16 hours ago
-
Ray tracing through optical system of thick lenses
16 hours ago
- More from Physics Forums - Classical Physics
More news stories
Costs to treat stroke in America may double by 2030
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology
13 hours ago |
not rated yet |
0
New blood-thinner measures may cut medication errors
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology
16 hours ago |
not rated yet |
0
Registry questions superiority of bivalirudin over heparin
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology
16 hours ago |
not rated yet |
0
Study shows low rate of late lumen loss with bioresorbable DESolve device
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...
Cardiology
16 hours ago |
not rated yet |
0
Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology
May 21, 2013 |
5 / 5 (1) |
0
Rate of bicycle-related fatalities significantly lower in states with helmet laws
Existing research shows that bicyclists who wear helmets have an 88 percent lower risk of brain injury, but researchers at Boston Children's Hospital found that simply having bicycle helmet laws in place showed a 20 percent ...
Slowing the aging process—only with antibiotics
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Researchers complete largest genetic sequencing study of human disease
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
Having both migraines, depression may mean smaller brain
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
Novel approach for influenza vaccination shows promise in early animal testing
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...